What is IVA's current stock price?

IVA (Inventiva S.A.) is currently trading at $5.07 with a market cap of $263.5M.

What sector is Inventiva S.A. in?

Inventiva S.A. (IVA) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is IVA a good stock to buy?

Analysts have a Buy consensus on IVA with a price target of $16.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

IVA Inventiva S.A.

Healthcare

$5.07-2.69%ClosedMarket Cap: $263.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

-103.53

P/S

143.78

EV/EBITDA

-4.54

DCF Value

$-0.15

FCF Yield

-16.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

35.1%

Operating Margin

-3037.3%

Net Margin

-7899.6%

ROE

1870.4%

ROA

-141.9%

ROIC

-66.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q4 null	$28.8K	$-176.9M	$—
FY null	$4.5M	$-340.2M	$—
Q2 null	$4.5M	$-175.9M	$—
Q4 null	$6.5M	$-135.2M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$16.50

Target (Median)

$15.00

Target Range

$12.00 - $24.00

2 Strong Buy11 Buy0 Hold0 Sell0 Strong Sell

GuggenheimBuy

2025-11-18

HC Wainwright & Co.Buy

2025-10-09

Canaccord GenuityBuy

2025-09-30

GuggenheimBuy

2025-09-02

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.88

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Peers